Genotype-guided warfarin dosing study

Comparative study on standard and pharmacogenetic-guided initial dosing of warfarin in patients with prosthetic heart valves

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004586

Enrollment

200

Registered

2019-12-30

Start date

2013-01-21

Completion date

Unknown

Last updated

2020-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In this study, after receiving informed consent from the patient, 2.5 mg was administered to the standard dose group (age 65 or older or less than 50 kg) after being assigned to two groups of g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients requiring more than 3 months of warfarin after prosthetic valve replacement

Exclusion criteria

Exclusion criteria: 1) Minors under 20 years old 2) patients with severe liver disease or kidney disease 3) Patients with cancer and patients with risk of bleeding such as gastric ulcer

Design outcomes

Primary

Measure	Time frame
International Normalized Ratio	—

Secondary

Measure	Time frame
Time until therapeutic INR;bleeding complication	—

Countries

Korea, Republic of

Contacts

Public ContactKyung Eun Lee

Chungbuk National University

Outcome results